Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 15/20 | 1.00 |
| ▸ | CYP2C8 | P10632 | 2/20 | 0.80 |
| ▸ | MAPT | P10636 | 4/20 | 0.72 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.72 |
| ▸ | TP53 | P04637 | 2/20 | 0.72 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.65 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.65 |
| ▸ | PPARD | Q03181 | 1/20 | 0.65 |
| ▸ | PPARA | Q07869 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27188277 | 0.89 | PPARG (1.00) | PPARGCYP2C8PTGS2NR1I2PPARD | |
| SCHEMBL27188281 | 0.85 | PPARG (1.00) | PPARGCYP2C8MAPTSMN1; SMN2TP53 | |
| SCHEMBL27188270 | 0.85 | PPARG (1.00) | PPARGCYP2C8MAPTSMN1; SMN2TP53 | |
| SCHEMBL27188323 | 0.84 | PPARG (0.84) | PPARGCYP2C8MAPTSMN1; SMN2PTGS2 | |
| SCHEMBL27188335 | 0.84 | PPARG (0.84) | PPARGCYP2C8MAPTSMN1; SMN2TP53 | |
| SCHEMBL27188339 | 0.84 | PPARG (0.84) | PPARGCYP2C8MAPTSMN1; SMN2TP53 | |
| SCHEMBL27188299 | 0.83 | PPARG (0.80) | PPARGCYP2C8MAPTSMN1; SMN2TP53 | |
| SCHEMBL27188307 | 0.83 | PPARG (0.82) | PPARGCYP2C8MAPTSMN1; SMN2TP53 | |
| SCHEMBL27188305 | 0.81 | PPARG (0.79) | PPARGCYP2C8MAPTSMN1; SMN2TP53 | |
| SCHEMBL30782707 | 0.81 | PPARG (1.00) | PPARGCYP2C8MAPTPTGS2NR1I2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240109850-A1 | Covalent PPARG inverse-agonists | BAYER AKTIENGESELLSCHAFT (DE) | 2024-04-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240109850-A1 | Covalent PPARG inverse-agonists | PPARG, PPARD, PPARA | PPARG 1/4885CYP2C8 839/4885MAPT 4826/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.